

IgG Anti-PM/Scl-100

MARKER IN POLYMYOSITIS/SCLERODERMA OVERLAP SYNDROME

Clinical Background

- Anti-polymyositis/scleroderma-100 (anti-PM/Scl-100) IgG antibodies were originally described in patients with PM/Scl overlap syndrome and are considered rare markers for this and other connective tissues diseases.^{1,2}
- These antibodies are found predominantly in patients with PM/Scl overlap syndrome and in about 3–10 percent of individuals with systemic sclerosis (SSc), polymyositis (PM), or dermatomyositis (DM).^{1,3-4} Antibodies may also occur in the absence of these diseases.¹
- Clinically, antibody-positive patients have a benign course of disease, are responsive to low to moderate dose of corticosteroid treatment, and exhibit a higher incidence of muscular involvement, Raynaud phenomenon, arthritis, and interstitial lung disease.^{1,5}

Indications for Ordering

Patients with clinical manifestations suggestive of systemic sclerosis/scleroderma and/or idiopathic inflammatory myopathies.

Interpretation

A positive anti-PM/Scl-100 IgG antibody result ≥ 11 units by immunoblot in association with an anti-nuclear antibody (ANA) nucleolar pattern by IFA suggests PM/Scl overlap syndrome, SSc, PM, or DM.

Limitations

- Test results alone are not diagnostic. Results should be used in conjunction with other clinical findings.
- Negative results do not rule out these diseases.

Methodology

IgG anti-PM/Scl-100 antibodies are detected using standard immunoblotting techniques and measured semi-quantitatively via band intensity.

Related Tests

- [Anti-Nuclear Antibodies \(ANA\), IgG Screen with Reflex to IFA Titer \(0050080\)](#)
- [Connective Tissue Diseases Profile \(0051668\)](#)

References

1. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. *Arthritis Res Ther* 2003;5(2):80–93.
2. Steven VD. Autoantibodies in systemic sclerosis. *Semin Arthritis Rheum* 2005;35(1):35–42.
3. Brouwer R, et al. Autoantibody profiles in the sera of European patients with myositis. *Ann Rheum Dis* 2001;60(2):116–23.
4. Hanke K, et al. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. *Arthritis Res Ther* 2009;11(1):R22.
5. Vanderghynst F, et al. Anti-pm/scl antibodies in connective tissue disease: Clinical and biological assessment of 14 patients. *Clin Exp Rheumatol* 2006;24(2):129–33.

Test Information

2003040 **PM/Scl-100 Antibody, IgG, with Reflex to ANA IFA**

For specific collection, transport, and testing information, refer to the ARUP website at www.aruplab.com.

For information on test selection, ordering, and interpretation, refer to ARUP Consult[®] at www.arupconsult.com.